Much of the initial research published by our and other groups have recently revealed the doublecortin-like kinase 1 (DCLK1) antigens as valuable predictive biomarkers and suitable candidates for tumor immunotherapy in terms of their role in regulating diverse tumorigenesis pathways [7–10]. This evidence concerns the gene DCLK1 and neoplasm.